Long-term HIV dynamics subject to continuous therapy and structured treatment interruptions

被引:46
作者
Hadjiandreou, Marios M. [1 ]
Conejeros, Raul [2 ]
Wilson, D. Ian [1 ]
机构
[1] Univ Cambridge, Dept Chem Engn, New Museums Site, Cambridge CB2 3RA, England
[2] Pontificia Univ Catolica Valparaiso, Escuela Ingn Bioquim, Valparaiso, Chile
关键词
Mathematical modelling; Optimal control; Chemotherapy; Drug resistance; HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; DRUG-RESISTANT HIV-1; REVERSE-TRANSCRIPTASE; TREATMENT REGIMENS; ANTIVIRAL THERAPY; PERIPHERAL-BLOOD; STOPPING THERAPY; UNITED-KINGDOM; IMMUNE-SYSTEM;
D O I
10.1016/j.ces.2008.12.010
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
This study involves the mathematical modelling of long-term HIV dynamics and the investigation of optimal treatment strategies. In our previous work, we produced a model which replicates literature-reported clinical data from untreated patients with good agreement and is able to predict the entire trajectory of the disease. Here, we extend the model to account for therapy and the emergence of virus resistant to antiretroviral drugs. We compare the new model with clinical data and use it to investigate the effect of continuous and interrupted (structured treatment interruptions, STI) therapy. For the former, there exist optimal combinations of reverse transcriptase inhibitor (RTI) and protease inhibitor (PI) drug efficacies for which both the wild-type (drug-sensitive) virus is depleted and the time at which mutated (drug-resistant) virus becomes dominant is extended. The simulation results also suggest that 'PI-based' drug regimes work better than 'RTI-based' ones. For STIs, there exists an optimised schedule of ON and OFF treatment by which the interplay between drug-sensitive and drug-resistant virus does not allow either of them to grow in an uncontrolled manner and deplete CD4+ T-cells (the main target of HIV: they 'orchestrate' the immune response). Furthermore, the schedule minimises the impact of side-effects that may arise during therapy. The results show that an optimised schedule, facilitating the interplay between the two virus strains, is the key to the successful implementation of STIs, which have so far been unsuccessful in extending survival-time considerably. Whereas continuous therapy fails when treating patients that have developed strong drug resistance, STIs prove to be very promising. The simulation and optimisation results indicate that although complete eradication of the virus may not be possible, controlling it over a considerable length of time is feasible. (c) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1600 / 1617
页数:18
相关论文
共 79 条
[1]   Interruption of antiretroviral therapy to augment immune control of chronic HIV-1 infection: Risk without reward [J].
Abbas, UL ;
Mellors, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13377-13378
[2]   HIV dynamics: Modeling, data analysis, and optimal treatment protocols [J].
Adams, BM ;
Banks, HT ;
Davidian, M ;
Kwon, HD ;
Tran, HT ;
Wynne, SN ;
Rosenberg, ES .
JOURNAL OF COMPUTATIONAL AND APPLIED MATHEMATICS, 2005, 184 (01) :10-49
[3]  
Adams BM, 2004, MATH BIOSCI ENG, V1, P223
[4]  
[Anonymous], 2006, Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents, P1
[5]   Predicting differential responses to structured treatment interruptions during HAART [J].
Bajaria, SH ;
Webb, G ;
Kirschner, DE .
BULLETIN OF MATHEMATICAL BIOLOGY, 2004, 66 (05) :1093-1118
[6]   Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption [J].
Barreiro, P ;
de Mendoza, C ;
González-Lahoz, J ;
Soriano, V .
CLINICAL INFECTIOUS DISEASES, 2005, 41 (06) :897-900
[7]  
Blackham J, 2005, AIDS, V19, P487, DOI 10.1097/01.aids.0000162337.58557.3d
[8]   Virus dynamics and drug therapy [J].
Bonhoeffer, S ;
May, RM ;
Shaw, GM ;
Nowak, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6971-6976
[9]   Estimating the proportion of patients infected with HIV who wilt die of comorbid diseases [J].
Braithwaite, RS ;
Justice, AC ;
Chang, CCH ;
Fusco, JS ;
Raffanti, SR ;
Wong, JB ;
Roberts, MS .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (08) :890-898
[10]  
Cane P, 2005, BMJ-BRIT MED J, V331, P1368, DOI 10.1136/bmj.38665.534595.55